The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma
Marios Papadimitriou, MD, University of Miami, Miami, FL, discusses the genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma. Dr Papadimitriou reports on differential gene expression between three patient groups: hyper-APOBEC with MAF translocation, hyper-APOBEC without MAF translocation, and non-hyper-APOBEC without MAF translocation. Dr Papadimitriou then describes how disturbances in the pathways regulating the DREAM complex can lead to over-expression of APOBEC3B, and discusses the identification of genes correlated with APOBEC3B. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
